Navigation Links
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Date:10/25/2010

the Company's previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment). The SUPPORTS trial is being conducted at major transplant centers throughout the US, Europe, and Australia and is expected to complete in the second half of 2011.  The trial is the subject of a Special Protocol Assessment (SPA) agreement that the Company reached with the US Food and Drug Administration (FDA).

orBec® was the subject of two prior randomized, double-blind, placebo-controlled clinical trials in acute GI GVHD. The first study was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139).  At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, p-value 0.04).

orBec® represents a first-of-its-kind oral, locally acting thera
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Calif. , Nov. 26, 2014   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and CEO of Regulus, will ... Annual Piper Jaffray Healthcare Conference at the New York ... p.m. EST.  The presentation will be webcast at the ...
(Date:11/26/2014)... 2014 Scott Steiger lives in ... As an engineer for the past 20 years, he,s traveled extensively ... service. He,s been to six of the seven continents. Travel is ... http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... a pretty good idea of what,s required. His latest ...
(Date:11/26/2014)... a leader in the development of Chimeric Antigen Receptors ... cancers, today announced the completion of a series A ... -based healthcare private equity fund.   CARsgen ... new therapeutics for liver, lung, stomach and brain cancers. ... Hospital, the company plans to initiate clinical studies for ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2CARsgen Completes Series A Financing 2
(Date:11/27/2014)... and Caicos Islands; BWI (PRWEB) November 28, 2014 ... the Tuscany Resort in the Turks & Caicos. ... by TripAdvisor in Providenciales, is announcing a few highly ... bedroom villa rentals. And they are offering every ... , Additionally, The Tuscany, is having a January ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Luciana Lagana ... to be part of Omadox, a feature film that received ... an award for best ensemble cast. It is also an ... a great start to a successful cinematic career for James ... white movies. If you enjoy experimental mystery, filmed in glorious ...
(Date:11/27/2014)... "As a nurse I see patients ... urinary incontinence," said an inventor from Whiting, N.J. "I ... accessory to prevent leakage and keep them dry and ... leakage. This prevents stains on pants, skirts and bottoms, ... ensures that the individual has time to get to ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Tylenol lawsuits ... were allegedly injured by the medication are continuing to ... litigation is looking ahead to a status conference in ... a Scheduling Order issued earlier this year, a conference ... 16th at 10:00 a.m. Items likely to be discussed ...
Breaking Medicine News(10 mins):Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3
... shift workers or those with narcolepsy, scientists say , FRIDAY, ... called orexin-A may be key to undoing the negative mental ... , Orexin-A is a peptide (a kind of protein) made ... at the Wake Forest University School of Medicine in Winston-Salem, ...
... free online until March, presents key articles of interest to ... consider the history of leukemia, and how different ... children , describe new research based ... for treatment to target these sub-types more precisely ...
... State,s Highest Honor for Organizational Performance Excellence, ... Council (MQC) announces Oakwood Healthcare, Inc. as a ... Leadership Award is the highest honor for,organizational performance ... a,rigorous review by a team of examiners who ...
... J. Fox,Foundation has committed up to $3.8 million ... treat Parkinson,s disease by reducing expression,of the protein ... Farrer,PhD, of Mayo Clinic Jacksonville (Florida) with collaborators ... Center will work,to optimize a small interfering RNA ...
... Nurse-to-Patient Staffing Ratios, Ability for Nurses to ... Advocate for Urgent Patient Safety Measures, PHOENIX, Jan. 4 ... major legislation to,make Arizona hospitals safer for patients and strengthen ... patient protections., HB 2041, the Arizona Patient Protection Act, ...
... If index finger is shorter than ring finger you might be ... Women whose index finger is shorter than their ring finger are ... In fact, having a shorter index finger may double the risk ... , The ratio of index finger length to ring finger ...
Cached Medicine News:Health News:Protein Nasal Spray Revives Sleep-Deprived Monkeys 2Health News:Michigan Quality Council (MQC) Names Oakwood Healthcare Inc. 2007 State Quality Award Recipient 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 3Health News:Arizona Patient Protection Act Introduced 2Health News:Arizona Patient Protection Act Introduced 3Health News:Fingers Point to Risk for Arthritic Knees 2
... matter what cement youre using, the Vortex Vacuum ... mix. Vortex is stirring up traditional vacuum mixers. ... mix every time. The time-saving crank three ... means less effort and less stirring, cutting down ...
The OsteoJect Bone Cement Delivery System now offers leading technology to physicians with the first-ever reusable driver. The OsteoJect allows precise delivery of bone cement under active fluoro whi...
... Davol has worked in partnership with clinicians ... the benefits of autologous blood to patients. ... autotransfusion reaches new levels of simplicity while ... - resulting in new levels of confidence ...
... for rugged use; perfect tool with power ... helps reduce user fatigue. Internally lubricated for ... so that it will not break if ... extending blade life by 50% compared to ...
Medicine Products: